Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 7/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.56 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | PNP | P00491 | 1/20 | 0.54 |
| ▸ | KRAS | P01116 | 7/20 | 0.52 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6363921 | 0.92 | HINT1 (0.65) | HINT1TAS1R3TAS1R1GSK3ARPS6KA3 | |
| SCHEMBL2337631 | 0.90 | HINT1 (0.61) | HINT1TAS1R3TAS1R1GSK3ARPS6KA3 | |
| SCHEMBL6397385 | 0.88 | HINT1 (0.61) | HINT1TAS1R3TAS1R1GSK3ARPS6KA3 | |
| SCHEMBL1611244 | 0.88 | HINT1 (0.77) | HINT1GSK3ARPS6KA3MAPK14NT5E | |
| SCHEMBL25241066 | 0.87 | HPGD (0.58) | HINT1TAS1R3TAS1R1GSK3ARPS6KA3 | |
| SCHEMBL26067723 | 0.87 | HPGD (0.58) | HINT1TAS1R3TAS1R1GSK3ARPS6KA3 | |
| SCHEMBL1058400 | 0.87 | HPGD (0.58) | HINT1TAS1R3TAS1R1GSK3ARPS6KA3 | |
| SCHEMBL25524 | 0.87 | HPGD (0.58) | HINT1TAS1R3TAS1R1GSK3ARPS6KA3 | |
| SCHEMBL5661883 | 0.87 | HINT1 (0.56) | HINT1TAS1R3TAS1R1GSK3ARPS6KA3 | |
| SCHEMBL18007485 | 0.87 | TAS1R3 (0.68) | HINT1TAS1R3TAS1R1NT5EKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401852-B1 | METHODS FOR PREPARING OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHOROTHIOATE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2013-09-11 | — | — | EP | disclosed |
| EP-1401852-A4 | METHODS FOR PREPARING OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHOROTHIOATE LINKAGES | ISIS PHARMACEUTICALS INC (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1401852-A2 | METHODS FOR PREPARING OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHOROTHIOATE LINKAGES | ISIS Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030069410-A1 | Methods for preparing oligonucleotides having chiral phosphorothioate linkages | ISIS PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002102815-A2 | METHODS FOR PREPARING OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHOROTHIOATE LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069410-A1 | Methods for preparing oligonucleotides having chiral phosphorothioate linkages | RNGTT, TYMP, POLN | HINT1 575/4885TAS1R3 4761/4885TAS1R1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.